Zhongsheng Pharmaceutical: Announcement of Resolutions of the First Meeting of the Ninth Board of Directors
Securities code: 002317 Announcement number: 2025-121
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Announcement of Resolutions of the First Meeting of the Ninth Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 2025 fourth extraordinary shareholders' meeting and employee representative meeting on December 29, 2025, and elected members of the company's ninth board of directors. In order to ensure the continuity of the work of the board of directors, the meeting notice of the first meeting of the ninth board of directors was delivered to all directors by person and email pre-notification on December 24, 2025. The meeting was held in 2025 On December 29, 2018, voting was held in the company's conference room through on-site and communication voting. 9 directors should be present at this meeting, but 9 directors were actually present. As unanimously recommended by all directors, the meeting was chaired by Mr. Chen Yonghong, and the secretary of the board of directors attended the meeting. The convening and holding of this meeting complied with the relevant provisions of laws, regulations and the Articles of Association. After careful deliberation by the directors present at the meeting and voting by registered vote, the following resolutions were made:
1. The "Proposal on the Election of Chairman of the Company's Ninth Board of Directors" was reviewed and approved.
The members of the company's ninth board of directors have been elected at the company's fourth extraordinary shareholders' meeting and employee representative meeting in 2025. At this meeting, Mr. Chen Yonghong was elected as the chairman of the ninth board of directors of the company, and his term is the same as that of the current board of directors.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
Note: For details of Mr. Chen Yonghong's resume, please refer to the "Announcement of Resolutions of the 29th Meeting of the Eighth Board of Directors" published by the company on December 12, 2025 in the information disclosure media: "Securities Times", "Shanghai Securities News" and cninfo.com (www.cninfo.com.cn).
2. The "Proposal on the Election of Vice Chairman of the Company's Ninth Board of Directors" was reviewed and approved.
The members of the company's ninth board of directors have been elected at the company's fourth extraordinary shareholders' meeting and employee representative meeting in 2025. At this meeting, Ms. Zhang Yuchong was elected as the vice chairman of the ninth board of directors of the company, with a term of office equal to
Page 1 of 7
Securities code: 002317 Announcement number: 2025-121
This board of directors is unanimous.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
Note: For details of Ms. Zhang Yuchong's resume, please refer to the company's "Announcement of Resolutions of the 29th Meeting of the Eighth Board of Directors" published by the company on December 12, 2025 in the information disclosure media: "Securities Times", "Shanghai Securities News" and cninfo.com (www.cninfo.com.cn).
- The "Proposal on the Election of Members of the Special Committees of the Company's Ninth Board of Directors" was reviewed and approved.
The members of the company's ninth board of directors have been elected at the company's fourth extraordinary shareholders' meeting and employee representative meeting in 2025. In order to standardize the company's operations, in accordance with the provisions of the "Code of Corporate Governance for Listed Companies", the Articles of Association and the implementation rules of the special committees of the board of directors, this meeting elected members of the strategy and investment committee, nomination committee, remuneration and assessment committee and audit committee of the ninth board of directors and other special committees, with the same terms as the current board of directors. It is agreed that the specific composition of the special committees of the board of directors is as follows:
Strategy and Investment Committee: It consists of 9 directors, including non-independent director Mr. Chen Yonghong, non-independent director Ms. Zhang Yuchong, non-independent director Ms. Long Chunhua, non-independent director Mr. Shan Pengan, non-independent director Ms. Wang Luman, employee director Mr. Huang Hougan, independent director Mr. Liu Yunguo, independent director Ms. Tao Jianhong, and independent director Mr. Jiang Baoguo. Among them, non-independent director Mr. Chen Yonghong serves as the chairman (convener).
Nomination Committee: It consists of 3 directors, including independent director Ms. Tao Jianhong, independent director Mr. Liu Yunguo, and non-independent director Mr. Chen Yonghong. Among them, independent director Ms. Tao Jianhong serves as the chairman (convener).
Remuneration and Appraisal Committee: It consists of 3 directors, including independent director Mr. Jiang Baoguo, independent director Ms. Tao Jianhong, and non-independent director Ms. Long Chunhua. Among them, independent director Mr. Jiang Baoguo serves as the chairman (convener).
Audit Committee: It consists of 3 directors, including independent director Mr. Liu Yunguo, independent director Mr. Jiang Baoguo, and non-independent director Mr. Shan Pengan. Among them, independent director Mr. Liu Yunguo serves as the chairman (convener).
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
Note: For details of the personal resumes of the above members, please see the company's information disclosure media published on December 12, 2025 and December 30, 2025: "Securities Times", "Shanghai Securities News" and cninfo.com
Page 2 of 7
Securities code: 002317 Announcement number: 2025-121
(www.cninfo.com.cn) "Announcement on Resolutions of the 29th Meeting of the Eighth Board of Directors" and "Announcement on the Election of Employee Representative Directors".
4. The "Proposal on Appointing the President of the Company" was reviewed and approved.
After nomination by the chairman and review by the nomination committee of the board of directors, this meeting agreed to appoint Mr. Chen Yonghong as president of the company, with a term consistent with the current board of directors.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
5. The "Proposal on Appointment of Vice President of the Company" was reviewed and approved.
After nomination by the president and review by the nomination committee of the board of directors, this meeting agreed to appoint Ms. Zhang Yuchong as the company's senior vice president, and agreed to appoint Ms. Long Chunhua, Mr. Liu Shuang, Mr. Luo Rikang and Mr. Chen Xiaoxin as the company's vice presidents, with the same terms as the current board of directors.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
Note: For detailed resumes of Ms. Zhang Yuchong and Ms. Long Chunhua, please refer to the company’s “Announcement on Resolutions of the 29th Meeting of the Eighth Board of Directors” published on December 12, 2025 in information disclosure media: Securities Times, Shanghai Securities News and Juchao Information Network (www.cninfo.com.cn). Please see the attachment for the personal resumes of Mr. Liu Shuang, Mr. Luo Rikang and Mr. Chen Xiaoxin.
6. The "Proposal on Appointment of Secretary to the Company's Board of Directors" was reviewed and approved.
After nomination by the chairman and review by the nomination committee of the board of directors, this meeting agreed to appoint Mr. Yang Wei as secretary of the company's board of directors, with a term consistent with the current board of directors.
Yang Wei’s contact information is as follows:
Contact address: Information Industrial Park, Xihu Industrial Zone, Shilong Town, Dongguan City, Guangdong Province
Contact number: 0769-86188130
Fax number: 0769-86188082
Email: [email protected]
Postal code: 523325
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
Note: Please see the attachment for Mr. Yang Wei’s resume.
Page 3 of 7
Securities code: 002317 Announcement number: 2025-121
7. The "Proposal on the Appointment of the Company's Financial Director" was reviewed and approved.
After nomination by the president, review by the nomination committee of the board of directors, and review and approval by the audit committee of the board of directors, this meeting agreed to appoint Ms. Long Chunhua as the company's financial director, with a term consistent with the current board of directors.
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions.
Documents available for inspection
A resolution of the board of directors signed by the directors present and stamped with the seal of the board of directors.
Announcement is hereby made.
Board of Directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd. December 29, 2025
Page 4 of 7
Securities code: 002317 Announcement number: 2025-121
Attachment: Resume
- Liu Shuang: Chinese nationality, no permanent overseas residence, male, born in January 1977, MBA from the United Business School in Belgium. He once served as executive deputy general manager of Nanjing Tongrentang Pharmaceutical Co., Ltd., consultant of Beijing Qunying Management Consulting Co., Ltd., and general manager of Beijing Zhongrui Xinkang Management Consulting Co., Ltd.; currently he is the company's vice president, general manager of the Marketing Management Center, general manager of Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd., executive director and manager of Guangzhou Tangwang Medical Technology Co., Ltd., and director of Guangdong Yishu Pharmaceutical Co., Ltd.
Mr. Liu Shuang does not directly hold shares in the company and has no relationship with shareholders, actual controllers who hold more than 5% of the company's shares, and other directors, supervisors, and senior managers of the company. Mr. Liu Shuang does not fall under any of the circumstances stipulated in Article 146 of the Company Law, nor does he fall under Article 3.2.2 of the "Self-Regulatory Guidelines No. 1 - Standardized Operation of Main Board Listed Companies" Those who are not allowed to be nominated as directors or supervisors as stipulated in paragraph 1 of the Article have not been banned from the securities market by the China Securities Regulatory Commission or have been publicly identified as unfit to serve as directors, supervisors or senior managers of listed companies by the stock exchanges. In the past three years, they have not been subject to administrative penalties by the China Securities Regulatory Commission and have not been publicly condemned or criticized by more than three notices by the stock exchanges. They have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations. Mr. Liu Shuang is not a "person subject to execution for breach of trust".
- Luo Rikang: Chinese nationality, no permanent right of residence abroad, male, born in December 1975, bachelor's degree from China Pharmaceutical University, licensed pharmacist and pharmaceutical engineer. He once served as the manager of the company's operation management department, assistant general manager of the production and manufacturing center, assistant to the company's senior president, chairman of the company's board of supervisors, deputy general manager of Guangdong Xianqiang Pharmaceutical Co., Ltd., supervisor of Guangdong Yishu Pharmaceutical Co., Ltd., and supervisor of Guangdong South China Pharmaceutical Group Co., Ltd.; currently he is the company's vice president, general manager of the production and manufacturing center, chairman of Guangdong Yishu Pharmaceutical Co., Ltd., and supervisor of Guangdong Xianqiang Pharmaceutical Co., Ltd.
Mr. Luo Rikang directly holds 10,000 shares of the company, accounting for 0.0012% of the company's total shares. He has no relationship with shareholders, actual controllers who hold more than 5% of the company's shares, and other directors and senior managers of the company. Mr. Luo Rikang does not fall under any of the circumstances stipulated in Article 178 of the Company Law, nor does he fall under Article 3.2.2 of the Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies. Those who are not allowed to be nominated as directors or senior managers as stipulated in paragraph 1 of the Article have not been banned from the securities market by the China Securities Regulatory Commission or have been publicly identified as unsuitable to serve as directors or senior managers of listed companies by the stock exchanges. They have not been subject to administrative penalties by the China Securities Regulatory Commission or been publicly condemned by the stock exchanges or criticized by three or more notifications in the past thirty-six months. They have not been criticized by the judicial authorities for suspected crimes.
Page 5 of 7
Securities code: 002317 Announcement number: 2025-121
Regarding the opening of a case for investigation or the case of being investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations. Mr. Luo Rikang is not a "person subject to execution for breach of trust".
- Chen Xiaoxin: Chinese nationality, no permanent overseas residence, male, born in April 1979, holds a doctorate in medicine from Guangzhou University of Traditional Chinese Medicine, a doctorate in engineering from Sun Yat-sen University, and holds the title of senior pharmaceutical engineer. He once served as the director of the company's innovative drug division, deputy general manager of the R&D center, and president of Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.; he is currently the general manager of the company's R&D center and chairman of Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.
Mr. Chen Xiaoxin does not directly hold shares in the company and has no relationship with shareholders, actual controllers who hold more than 5% of the company's shares, and other directors and senior managers of the company. Mr. Chen Xiaoxin does not fall under any of the circumstances stipulated in Article 178 of the "Company Law", nor does he fall under Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies" Those who are not allowed to be nominated as directors or senior managers as stipulated in paragraph 1 of the Article have not been banned from the securities market by the China Securities Regulatory Commission or have been publicly identified as unsuitable to serve as directors or senior managers of listed companies by the stock exchanges. They have not been subject to administrative penalties by the China Securities Regulatory Commission and have not been publicly condemned or criticized by more than three notices by the stock exchanges in the past 36 months. They have not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations. Mr. Chen Xiaoxin is not a “person subject to execution for breach of trust”.
- Yang Wei: Chinese nationality, no permanent right of residence abroad, male, born in 1988, bachelor's degree from South China University of Technology, master's degree from Fudan University. He once worked for Shanghai Fosun Changzheng Medical Science Co., Ltd., Product Manager of the Medical Marketing Department and Director of the Prescription Drug Marketing Department of Guangdong Zhongsheng Pharmaceutical Trading Co., Ltd.; currently he is the secretary of the board of directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd.; he is also the deputy director of the Investor Relations Committee of the Dongguan Listed Companies Association, a member of the Pharmaceutical Innovation Investment Professional Committee of the China Pharmaceutical Innovation Promotion Association, a director of the Guangdong South China New Drug Creation Center, and a member of the Executive Committee of Lingzhi Angel Investment.
Mr. Yang Wei does not directly hold shares in the company and has no relationship with shareholders, actual controllers who hold more than 5% of the company's shares, and other directors and senior managers of the company. There is no "Company Law" for Mr. Yang Wei
One of the circumstances stipulated in Article 178: There is no circumstance that prohibits nomination as a director or senior manager as stipulated in the first paragraph of Article 3.2.2 of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies", and there is no ban on securities market entry measures taken by the China Securities Regulatory Commission or being banned from the securities market. The exchange has publicly determined that the person is not suitable to serve as a director or senior manager of a listed company, has not been subject to administrative punishment by the China Securities Regulatory Commission, has not been publicly reprimanded by the stock exchange or criticized three times or more in the past 36 months, and has not been investigated by the judicial authorities for suspected crimes or has been investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations.
Page 6 of 7 Securities code: 002317 Announcement number: 2025-121 Case investigation situation. Mr. Yang Wei does not belong to the category of "persons subject to execution for breach of trust".
Page 7 of 7